Evidence map›Paper›PMID 37401875›Full record

ArticleMolecular carcinogenesis2023

IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.

Brianna L Hill, Alyssa N Calder, Joseph P Flemming, Yiyang Guo, Sydney L Gilmore, Melissa A Trofa, Sean K Daniels, Torbjoern N Nielsen, Laura K Gleason, Zoya Antysheva and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Brianna L HillDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Alyssa N CalderDepartment of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Joseph P FlemmingDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Yiyang GuoDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sydney L GilmoreDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Melissa A TrofaSidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sean K DanielsSidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Torbjoern N NielsenJohn A. Burns School of Medicine, University of Hawai'i at Mānoa Honolulu, Honolulu, USA.
Laura K GleasonSidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Zoya AntyshevaBostonGene Corporation, Waltham, Massachusetts, USA.
Ksenia DeminaBostonGene Corporation, Waltham, Massachusetts, USA.
Nikita KotlovBostonGene Corporation, Waltham, Massachusetts, USA.
Christopher J H DavittBostonGene Corporation, Waltham, Massachusetts, USA.
David M CognettiDepartment of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
George C PrendergastLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
Adam E SnookDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Jennifer M JohnsonDepartment of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Gaurav KumarDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Alban J LinnenbachDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Ubaldo Martinez-OutschoornDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Andrew P SouthDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Joseph M CurryDepartment of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Larry A HarshyneDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Adam J LuginbuhlDepartment of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Mỹ G MahoneyDepartment of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Thomas Jefferson University · USRepligen (United States) · USAddgene · USLankenau Institute for Medical Research · USUniversity of Hawaiʻi at Mānoa · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Claudio Guillermo Giraudo · 1995 to 2026
$94.8M
Alcohol Tissue InjuryT32AA007463 · NIAAA · THOMAS JEFFERSON UNIVERSITY · PI HOEK, JOANNES B, VADIGEPALLI, RAJANIKANTH · 1985 to 2021
$9.1M
Effects of extracellular vesicles on miRNA activity in the skinR01AR074314 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI MAHONEY, MY GEORGIA · 2018 to 2022
$1.7M
The Role of sEV-associated miR-146a in Tissue RepairF31AR080564 · NIAMS · THOMAS JEFFERSON UNIVERSITY · PI HILL, BRIANNA LEIGH · 2022 to 2023
$94k
NCI NIH HHS P30 CA056036NIAAA NIH HHS T32 AA007463NIAMS NIH HHS F31 AR080564NIAMS NIH HHS R01 AR074314
6 · The paper itself

Abstract

Therapy using anti-PD-1 immune checkpoint inhibitors (ICI) has revolutionized the treatment of many cancers including head and neck squamous cell carcinomas (HNSCC), but only a fraction of patients respond. To better understand the molecular mechanisms driving resistance, we performed extensive analysis of plasma and tumor tissues before and after a 4-week neoadjuvant trial in which HNSCC patients were treated with the anti-PD-1 inhibitor, nivolumab. Luminex cytokine analysis of patient plasma demonstrated that HPV

Indexed as

Extracellular VesiclesHead and Neck NeoplasmsMicroRNAsPapillomavirus InfectionsHumansInterleukin-8Neoadjuvant TherapyNivolumabSquamous Cell Carcinoma of Head and NeckInterleukin-8MicroRNAsNivolumabchemokinedesmogleinextracellular vesicleimmune checkpoint inhibitormicroRNA

Identifiers

PMID37401875
PMCPMC10524928
OpenAlexW4383058961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.